{"id":934351,"date":"2026-02-04T17:15:58","date_gmt":"2026-02-04T22:15:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/"},"modified":"2026-02-04T17:15:58","modified_gmt":"2026-02-04T22:15:58","slug":"the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/","title":{"rendered":"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Feb.  04, 2026  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Vistagen Therapeutics, Inc. (NASDAQ: VTGN).<\/strong><\/p>\n<p>Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ijchROmgpfv5v6ZYD7Zgctb5jk7FqET5Gxjyp7uedvJG_PJ9K9O0qInUDPP3dbExX84UBy2Y4wJZcsqdPQ9fKDdjJUQEncuWIi_DnojuNXeqsgKTCvGKB9B9qlQ4Z0pB221yv9yY8qKVmefaNw1229VfU0KS2BUn-_eUgyK3ESIDSl5Be3Ebo_rv4yXth1SZLmNBofaDKW5yR3jnYNPEpDvnp22qbScCGSGacwqVkgD9BCcXEOK3XqXPeJ-BoH2Q1hdPF8jy39BtGnNUWwdj4sKxYlL6YiEvIAA_nXW3j8kmBleo8PKklJpYQq-2bBktLW_CSeKVTdGygiq9A41N-Q==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/vistagen-therapeutics-inc-loss-submission-form\/?id=183336&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>April 1, 2024 to December 16, 2025<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder. On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Subjective Units of Distress Scale. In pertinent part, defendants announced the trial did not achieve its primary endpoint and there was no treatment difference between fasedienol and placebo for the secondary endpoints. Following this news, the price of Vistagen\u2019s common stock declined dramatically from a closing market of $4.36 per share on December 16, 2025 to $0.86 per share on December 17, 2025, a decline of more than 80%.<\/p>\n<p>\n        <strong>DEADLINE: March 16, 2026<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ijchROmgpfv5v6ZYD7Zgctb5jk7FqET5Gxjyp7uedvJG_PJ9K9O0qInUDPP3dbExX84UBy2Y4wJZcsqdPQ9fKDdjJUQEncuWIi_DnojuNXeqsgKTCvGKB9B9qlQ4Z0pB221yv9yY8qKVmefaNw1222XPtUCqgcODF_x7fCK3fn_ImSf4KX3TKh7T5uGcXsk6gaJ1nILmTY5sZSQPwy3Qn6pFrXEj7NWfZHmALNZpu8mE0t9-4EbRjQAbnhK4D3X2IBB102R6qzsOSYqYI2gP9rtYmA2HWrwnfGNleA0laV_QZF2MttFUsmxM6qrDdri7OGXx2NL2hARiBpdp6GQpGg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/vistagen-therapeutics-inc-loss-submission-form\/?id=183336&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of VTGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 16, 2026. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Oh4aknr067prVCZev08c9DOc-RYtoD35-KUpAVDCiCH5gHN5TvMfrLvU7CO05l1lohvLsxRZrzpnhsOdgpK13wDc7zk-DMC66u50B69zO1I3Bi19hDU2DFcMuCQGEEV7\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Njg0NDMxMzctOWMxNy00NzI5LWE2NzAtMGNhYTU2ZmNiMmYyLTEyNzA0NjctMjAyNi0wMi0wNC1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/vistagen-therapeutics-inc-loss-submission-form\/?id=183336&amp;from=3 CLASS PERIOD: April 1, 2024 to December 16, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-934351","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/vistagen-therapeutics-inc-loss-submission-form\/?id=183336&amp;from=3 CLASS PERIOD: April 1, 2024 to December 16, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social &hellip; Continue reading &quot;The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T22:15:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN\",\"datePublished\":\"2026-02-04T22:15:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/\"},\"wordCount\":459,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/\",\"name\":\"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=\",\"datePublished\":\"2026-02-04T22:15:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/","og_locale":"en_US","og_type":"article","og_title":"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN - Market Newsdesk","og_description":"NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/vistagen-therapeutics-inc-loss-submission-form\/?id=183336&amp;from=3 CLASS PERIOD: April 1, 2024 to December 16, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social &hellip; Continue reading \"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T22:15:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN","datePublished":"2026-02-04T22:15:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/"},"wordCount":459,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/","name":"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=","datePublished":"2026-02-04T22:15:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODM5NyM3NDA3OTQ1IzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-reminds-vistagen-therapeutics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-16-2026-vtgn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"The Gross Law Firm Reminds Vistagen Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 \u2013 VTGN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=934351"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934351\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=934351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=934351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=934351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}